Chronic Treatment of an Advanced Prostate-cancer Patient With Oral Methioninase Resulted in Long-term Stabilization of Rapidly Rising PSA Levels

xlomafota13 shared this article with you from Inoreader Chronic Treatment of an Advanced Prostate-cancer Patient With Oral Methioninase Resulted in Long-term Stabilization of Rapidly Rising PSA Levels Via In vivo (Athens, Greece) In Vivo. 2021 Jul-Aug;35(4):2171-2176. doi: 10.21873/invivo.12488. ABSTRACT BACKGROUND/AIM: Advanced prostate cancer is a recalcitrant disease with very limited treatment options. Our laboratory discovered methionine addiction, presumably a characteristic of all cancer types, including prostate cancer, which can be targeted by methionine restriction (MR), through treatment with oral recombinant methioninase (o-rMETase). PATIENTS AND METHODS: o-rMETase was produced by fermentation of recombinant E. coli containing the Pseudomonas putida methioninase gene, and purified by column chromatography. An advanced prostate cancer patient received o-rMETase as a supplement, 500 units per day, divided into two oral doses of 250 units each. RESULTS: Before treatment, the patient had a rapid rise in PSA levels, from 39 to 56 ng/ml, within 6 weeks. At the 15th week of o-rMETase administration, the PSA levels stabilized at 62 ng /ml. No overt side effects were observed. CONCLUSION: o-rMETase single treatment can be beneficial for advanced prostate cancer patients. PMID:34182494 | DOI:10.21873/invivo.12488 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.